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Background-—Acute kidney injury (AKI) has been associated with increased mortality in ST-segment elevation myocardial
infarction. We compared the mortality predictive accuracy of the 3 AKI definitions used most widely for patients with ST-segment
elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Methods and Results-—We included 3771 patients with ST-segment elevation myocardial infarction treated with primary
percutaneous coronary intervention at 2 Italian hospitals. AKI incidence was evaluated according to creatinine increases of ≥25%
(AKI-25), ≥0.3 mg/dL (AKI-0.3), and ≥0.5 mg/dL (AKI-0.5). The primary end point was in-hospital mortality. Overall, 557 (15%),
522 (14%), and 270 (7%) patients developed AKI-25, AKI-0.3, and AKI-0.5, respectively (P<0.01). All AKI definitions independently
predicted in-hospital mortality (adjusted odds ratio 4.9 [95% CI 3.1–7.8], 5.4 [95% CI 3.3–8.6], and 8.3 [95% CI 5.1–13.3],
respectively; P<0.01 for all). At receiver operating characteristic analysis, the addition of each AKI definition to combined clinical
predictors of mortality (age, sex, left ventricular ejection fraction, admission creatinine, creatine kinase-MB peak) found at stepwise
analysis significantly improved mortality prognostication (area under the curve increased from 0.89 for clinical predictor
combination alone to 0.92 for AKI-25, 0.92 for AKI-0.3, and 0.93 for AKI-0.5; P<0.01 for all). At reclassification analysis, AKI-0.5
added to clinical predictors, provided the highest score in mortality (net reclassification improvement +10% versus AKI-0.3
[P=0.01] and +8% versus AKI-25 [P=0.05]).
Conclusions-—Each AKI definition significantly improved the mortality prediction beyond major clinical variables. AKI-0.5 showed a
mortality discrimination advantage, suggesting it should be the preferred definition in studies addressing ST-segment elevation
myocardial infarction and focusing on short-term mortality. ( J Am Heart Assoc. 2016;5:e003522 doi: 10.1161/
JAHA.116.003522)
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P atients undergoing primary percutaneous coronary inter-vention (pPCI) for ST-segment elevation myocardial
infarction (STEMI) are at high risk of acute kidney injury
(AKI), a complication that is associated with a striking
increase in mortality.1–9 The AKI definitions that are most
widely used are relative (≥25%) and absolute (≥0.5 mg/dL)
increases in serum creatinine (sCr) concentration occurring in
the first 48 to 72 hours after hospital admission.10,11
Moreover, a lower threshold of absolute sCr increase
(≥0.3 mg/dL) was proposed recently to define AKI in patients
with both cardiovascular and noncardiovascular diseases.12,13
Although these definitions were shown to be closely associ-
ated with increased in-hospital mortality in STEMI patients
undergoing pPCI,1–10 no study has prospectively compared
them in terms of prognostic accuracy in a large cohort of
patients; therefore, it is still unclear which definition may
provide the best risk prognostication for STEMI patients.
Notably, the relationship between sCr and glomerular filtration
rate (GFR) is not linear.14,15 In patients with normal baseline
sCr, even a small absolute increase in sCr implies a significant
GFR reduction. In contrast, in patients with high baseline sCr,
a similar absolute increase of sCr is associated with a smaller
reduction in GFR. When relative changes in sCr are
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considered, a similar percentage reduction in GFR is foresee-
able, regardless of sCr baseline value.16 Consequently,
prognostic implications may differ according to the sCr
threshold chosen to define AKI.
The aim of this study was to compare the performance of
the most widely used AKI definitions in predicting in-hospital
mortality in a large cohort of STEMI patients undergoing pPCI.
Moreover, we investigated whether these definitions have any
additional value for improving the predictive accuracy of the
main clinical variables associated with mortality in this setting
and which AKI definitions performed better.
Methods
Study Population
The data analyzed in this study were obtained from prospec-
tively enrolled STEMI patients who underwent pPCI at Centro
Cardiologico Monzino in Milan, Italy, between January 1, 2002,
and August 1, 2015, and at Policlinico San Matteo in Pavia,
Italy, between January 1, 2005, and April 30, 2014. In general,
patients underwent pPCI if they had typical chest pain that
began within the previous 12 hours (24 hours for those with
cardiogenic shock) and at least 1-mm ST-segment elevation in
≥2 contiguous leads or a new left bundle-branch block. We
excluded patients in chronic peritoneal or hemodialysis
treatment, those undergoing emergency cardiac surgery,
and those who died during pPCI or before at least 2
consecutive sCr values were collected. The institutional
review boards of both centers approved the study, and all
patients gave written informed consent to the use of their
clinical data for research purposes.
Study Design
According to the clinical protocols of the 2 hospitals, sCr
values were measured in all patients by the Jaffe method at
hospital admission (before pPCI) and each day for the
following 72 hours. The total coefficients of variation for sCr
determinations were not >3%.
The incidence of AKI was evaluated in the first 72 hours
according to the following definitions: (1) a relative sCr
increase ≥25% from hospital admission value (AKI-25); (2) an
absolute sCr increase ≥0.3 mg/dL (AKI-0.3); (3) an absolute
sCr increase ≥0.5 mg/dL (AKI-0.5).
Echocardiogram was performed in all patients within
24 hours of hospital admission, and left ventricular ejection
fraction was calculated by the Simpson rule.17
The primary end point of the study was the occurrence of
in-hospital mortality. A composite clinical end point of death
and cardiogenic shock was considered as a secondary end
point. Other in-hospital major adverse clinical events (atrial
fibrillation, acute pulmonary edema, blood transfusions,
ventricular fibrillation, and ventricular tachycardia) were also
evaluated.
PCI Procedure
The pPCI procedure was performed by 24-hour on-call
interventional teams according to standard clinical practice.
Standard guide catheters (6F or 7F), guide wires, balloon
catheters, and coronary stents were used with a radial or
femoral approach. Periprocedural pharmacological therapy
and poststenting antithrombotic treatment were given accord-
ing to institutional protocols and guideline recommendations.
Statistical Analysis
Continuous variables are presented as meanSD and were
compared using the t test for independent samples. Variables
not normally distributed are presented as median and
interquartile ranges and were compared with the Wilcoxon
rank sum test. Categorical data were compared using the chi-
square or Fisher exact test, as appropriate.
A stepwise multivariable logistic model was developed to
identify the independent predictors of the primary end point.
Among the clinical variables found to be associated with AKI
occurrence independent of the definition used (age, sex,
weight, diabetes, hypertension, hyperlipidemia, smoking,
creatine kinase-MB peak, left ventricular ejection fraction,
admission sCr, GFR, anterior myocardial infarction location,
prior myocardial infarction, prior coronary artery bypass
grafting, and culprit lesion), the following remained indepen-
dently associated with in-hospital mortality: age, sex, creatine
kinase-MB peak, left ventricular ejection fraction, and admis-
sion sCr. Collinearity among the variables included in the
model was tested by the variance inflation factor. The
association between each AKI definition and in-hospital
mortality was assessed by logistic regression; analyses were
also adjusted for the combination of the above-mentioned
clinical variables. Results are presented as odds ratios (ORs)
with 95% CIs. Receiver operating characteristic curves were
calculated, and the area under the receiver operating
characteristic curve (AUC) with 95% CI was used to measure
the ability of the model to predict in-hospital mortality. AUCs
were compared as recommended by DeLong et al.18
Net reclassification improvement was used to identify the
best definition of AKI for the prediction of primary and
secondary end points when added to the combination of
clinical variables selected at the stepwise analysis. All tests
were 2-tailed, and P<0.05 was required for statistical
significance. All analyses were performed using SAS version
9.4 (SAS Institute). Reclassification statistics were assessed
with the SAS macros published by Cook and Ridker.19
DOI: 10.1161/JAHA.116.003522 Journal of the American Heart Association 2















 at IRCCS CENTRO CARDIOLOGICO on July 6, 2016http://jaha.ahajournals.org/Downloaded from 
Results
A total of 3771 STEMI patients treated with pPCI were
included in this study. Of them, 557 (15%) developed AKI-25,
522 (14%) developed AKI-0.3, and 270 (7%) developed AKI-0.5
(P<0.001 among the 3 definitions).
The clinical and laboratory characteristics of patients
with or without AKI, according to the 3 different definitions,
are listed in Table 1. Regardless of the definition used,
patients with AKI were older and were more likely to have
diabetes mellitus, larger infarct size, anterior STEMI, and
worse renal function at hospital admission than patients
without AKI.
Patients with AKI had a more complicated clinical course
and longer hospitalization (Table 2). In-hospital mortality
among our study participants was 4.1% (n=155). Figure 1
shows unadjusted and adjusted ORs for in-hospital mortality
using the 3 AKI definitions.
For the entire population, sensitivity and specificity for in-
hospital mortality were 55% (95% CI 48–63%) and 87% (95% CI
86–88%), respectively, for AKI-25; 58% (95% CI 50–66%) and
88% (95% CI 87–89%), respectively, for AKI-0.3; and 50% (95%
CI 42–58%) and 95% (95% CI 94–96%), respectively, for
AKI-0.5.
When the combination of independent predictors of
mortality found at multivariable stepwise analysis was eval-
uated in terms of accuracy to predict in-hospital mortality in
the entire population, the AUC was 0.89 (95% CI 0.87–0.92).
Figure 2 shows the AUCs for in-hospital mortality prediction
when each AKI definition was added to the combined clinical
variables. The addition of AKI with any of the 3 definitions
significantly improved in-hospital mortality prognostication
(P<0.01 for all comparisons). When the AUCs of the AKI
definitions in addition to clinical mortality predictors were
compared, the AUC associated with AKI-0.5 was significantly
higher than those of AKI-25 and AKI-0.3 (P<0.001 and
Table 1. Clinical and Laboratory Characteristics of the Study Patients According to AKI Definition
AKI-25 AKI-0.3 AKI-0.5
No (n=3214) Yes (n=557) P Value No (n=3249) Yes (n=522) P Value No (n=3501) Yes (n=270) P Value
Age, y 6212 6912 <0.001 6212 7012 <0.001 6312 7211 <0.001
Men, n (%) 2557 (80) 393 (71) <0.001 2569 (79) 381 (73) 0.002 2763 (79) 187 (69) <0.001
Weight, kg 7715 7413 <0.001 7714 7413 <0.001 7615 7312 <0.001
Diabetes mellitus, n (%) 487 (15) 109 (20) <0.001 485 (15) 111 (21) <0.001 533 (15) 63 (23) <0.001
Hypertension, n (%) 1636 (51) 341 (61) <0.001 1634 (50) 343 (66) 0.002 1793 (51) 184 (68) <0.001
Hyperlipidemia, n (%) 1366 (42) 181 (32) <0.001 1379 (42) 168 (32) <0.001 1467 (42) 80 (30) <0.001
Smoking, n (%) 1988 (62) 264 (47) <0.001 2026 (62) 226 (43) <0.001 2146 (61) 106 (39) <0.001
Anterior MI, n (%) 1470 (46) 316 (57) <0.001 1486 (46) 300 (57) <0.001 1619 (46) 167 (62) <0.001
Index PCI vessel, n (%) <0.001 <0.001 <0.001
LAD 1458 (45) 303 (54) 1473 (45) 288 (55) 1607 (46) 154 (57)
RCA 1160 (36) 160 (29) 1171 (36) 149 (29) 1251 (36) 69 (26)
LCx 541 (17) 78 (14) 550 (17) 69 (13) 586 (17) 33 (12)
Bypass graft 36 (1) 4 (1) 36 (1) 4 (1) 37 (1) 3 (1)
LM 19 (1) 12 (2) 19 (1) 12 (2) 20 (1) 11 (4)
Prior MI, n (%) 446 (14) 93 (17) 0.08 443 (14) 96 (18) 0.004 475 (14) 64 (24) <0.001
Prior CABG, n (%) 111 (3) 20 (4) 0.87 109 (3) 22 (4) 0.32 116 (3) 15 (6) 0.05
LVEF, % 4810 4112 <0.001 4810 4112 <0.001 4810 3812 <0.001
sCr, mg/dL 1 (0.9–1.1) 1 (0.8–1.3) 0.07* 1 (0.8–1.1) 1.1 (0.9–1.4) <0.001* 1 (0.8–1.1) 1.3 (1.0–1.6) <0.001*
sCr peak, mg/dL 1 (0.9–1.2) 1.5 (1.1–2.1) <0.001* 1 (0.9–1.2) 1.6 (1.3–2.3) <0.001* 1 (0.9–1.2) 2.2 (1.7–3.2) <0.001*
eGFR, mL/min per
1.73 m2
7922 7632 0.003 7922 6829 <0.001 8023 5825 <0.001
CK-MB peak, ng/mL 143 (59–278) 235 (103–409) <0.001* 140 (58–270) 240 (107–420) <0.001* 148 (61–283) 260 (107–444) <0.001*
AKI indicates acute kidney injury; AKI-0.3, absolute serum creatinine increase ≥0.3 mg/dL; AKI-0.5, absolute serum creatinine increase ≥0.5 mg/dL; AKI-25, relative serum creatinine
increase ≥25%; CABG, coronary artery bypass grafting; CK-MB, creatine kinase-MB isoenzyme; eGFR, estimated glomerular filtration rate (abbreviated MDRD equation); LAD, left anterior
descending; LCx, left circumflex; LM, left main; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; sCr,
serum creatinine.
*By nonparametric Wilcoxon rank sum test.
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P=0.03, respectively), without significant difference between
AKI-25 and AKI-0.3 (P=0.26). No difference in the AUC was
observed for the combination of AKI-25 or AKI-0.5 versus AKI-
0.5 alone when both were added to the clinical model
(P=0.69). At reclassification analysis, AKI-0.5 plus clinical
predictors provided the highest score in predicting mortality
(Table 3).
When the combination of independent predictors of
mortality was evaluated in terms of accuracy to predict the
secondary end point in the entire population, the AUC was
0.84 (95% CI 0.81–0.86). At reclassification analysis, the
combination of AKI-0.5 and clinical predictors again provided
the highest score (Table 3).
Discussion
The main finding of this study was that the AKI-0.5 definition
performed better for in-hospital mortality prognostication in
STEMI patients treated with pPCI than AKI-25 and AKI-0.3,
Table 2. In-Hospital Outcomes According to AKI Definition
AKI-25 AKI-0.3 AKI-0.5
No (n=3214) Yes (n=557) P Value No (n=3249) Yes (n=522) P Value No (n=3501) Yes (n=270) P Value
Death, n (%) 69 (2) 86 (15) <0.001 65 (2) 90 (17) <0.001 77 (2) 78 (29) <0.001
APE, n (%) 204 (6) 108 (19) <0.001 200 (6) 112 (21) <0.001 231 (7) 81 (30) <0.001
CS, n (%) 226 (7) 133 (24) 0.008 221 (7) 138 (26) 0.0002 253 (7) 106 (39) <0.001
AF, n (%) 302 (9) 113 (20) <0.001 298 (9) 117 (22) <0.001 338 (10) 77 (29) <0.001
VT/VF, n (%) 337 (10) 85 (15) 0.001 336 (10) 86 (16) <0.001 364 (10) 58 (21) <0.001
Blood transfusions, n (%) 82 (3) 55 (10) <0.001 84 (3) 53 (10) <0.001 91 (3) 46 (17) <0.001
CCU LOS, days 4 (3–5) 5 (4–8) <0.001* 4 (3–5) 5 (4–8) <0.001* 4 (3–5) 6 (4–10) <0.001*
Secondary end point†, n (%) 242 (8) 148 (27) <0.001 236 (7) 154 (29) <0.001 271 (8) 119 (44) <0.001
AF indicates atrial fibrillation; AKI, acute kidney injury; AKI-0.3, absolute serum creatinine increase ≥0.3 mg/dL; AKI-0.5, absolute serum creatinine increase ≥0.5 mg/dL; AKI-25, relative
serum creatinine increase ≥25%; APE, acute pulmonary edema; CCU, coronary care unit; CS, cardiogenic shock; LOS, length of stay; VF, ventricular fibrillation; VT, ventricular tachycardia.
*By nonparametric Wilcoxon rank sum test.
†In-hospital death and cardiogenic shock requiring intra-aortic balloon pump.
Figure 1. In-hospital mortality ORs and 95% CIs according to the 3 acute kidney injury definitions (AKI-25,
AKI-0.3, and AKI-0.5). Reported ORs are unadjusted and adjusted for age, sex, left ventricular ejection
fraction, creatine kinase-MB peak, and admission serum creatinine. AKI-0.3 indicates absolute serum
creatinine increase ≥0.3 mg/dL; AKI-0.5, absolute serum creatinine increase ≥0.5 mg/dL; AKI-25, relative
serum creatinine increase ≥25%; OR, odds ratio.
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even when added to clinical variables known to have critical
impact on prognosis.
Patients treated with pPCI represent a population at higher
risk for AKI for which renal prophylactic therapy, particularly
hydration, is unfeasible.1–9 To date, several AKI definitions
based on absolute and/or relative sCr increase have been
shown to be useful in predicting clinical outcome in STEMI1–9;
however, no study prospectively compared them in terms of
prognostic accuracy. To our knowledge, only 2 studies
investigated the incidence and associated mortality of 2 AKI
definitions in patients with STEMI undergoing pPCI.2,20
Nonetheless, the Risk, Injury, Failure, Loss, and End-stage
kidney disease (RIFLE) classification was 1 of the 2 definitions
used in both studies. RIFLE takes into account a ≥50%
increase in sCr, a criterion that has been investigated less
extensively in this specific clinical setting.16 Moreover,
because of a retrospective design,2 a small patient popula-
tion,20 and lack of mortality discrimination assessment,20 no
definite conclusion can be drawn about which AKI definition
should be preferred for mortality risk prediction in STEMI
patients.
In this study, we included a large population of STEMI
patients undergoing pPCI at 2 Italian centers, and we
prospectively compared the prognostic role of the AKI
definitions that are most widely used.10,13 In agreement with
previous studies, we found that AKI incidence ranged between
7% and 15% and was associated with 7- to 15-fold higher in-
hospital mortality based on the definition used, along with a
more complicated clinical course and a longer stay in the
coronary care unit.7–9,16 Notably, all 3 AKI definitions were
strongly associated with poor prognosis in our study popu-
lation. Regardless of the definition used, it is important to
know whether AKI occurrence provides prognostic informa-
tion beyond that carried by well-known independent clinical
predictors. The combination of variables identified by our
stepwise analysis accurately predicted mortality, with an AUC
of 0.89. This finding is not surprising because all of those
variables, either alone or in combination, were strongly
associated with patient outcome in this clinical setting.7,21–23
Nevertheless, the addition of each AKI definition to those
Figure 2. Receiving operating characteristic curves and corre-
sponding AUCs with 95% CIs for in-hospital mortality prediction in
the study patients, using a combination of prognostic clinical
variables alone and each acute kidney injury definition added to
clinical variables. The clinical variables that independently
predicted in-hospital mortality at stepwise analysis were age,
sex, left ventricular ejection fraction, creatine kinase-MB peak,
and admission serum creatinine. AKI-0.3 indicates absolute serum
creatinine increase ≥0.3 mg/dL; AKI-0.5, absolute serum crea-
tinine increase ≥0.5 mg/dL; AKI-25, relative serum creatinine
increase ≥25%; AUC, area under the curve.
Table 3. Reclassification Analysis Comparisons in the Prediction of Primary and Secondary End Points of the 3 AKI Definitions
Added to the Clinical Variables* Associated With In-Hospital Mortality
Model NRI % 95% CI P Value
Primary end point
AKI-0.5 plus independent predictors of mortality vs AKI-25 plus independent predictors of mortality 8.1 0.3–16.4 0.05
AKI-0.5 plus independent predictors of mortality vs AKI-0.3 plus independent predictors of mortality 10.0 2.0–18.0 0.01
AKI-25 plus independent predictors of mortality vs AKI-0.3 plus independent predictors of mortality 1.9 6.0 to 2.6 0.41
Secondary end point
AKI-0.5 plus independent predictors of mortality vs AKI-25 plus independent predictors of mortality 28.3 20.2–36.5 <0.001
AKI-0.5 plus independent predictors of mortality vs AKI-0.3 plus independent predictors of mortality 29.5 21.3–37.7 <0.001
AKI-25 plus independent predictors of mortality* vs AKI-0.3 plus independent predictors of mortality 28.5 20.3–36.7 <0.001
AKI indicates acute kidney injury, AKI-0.3, absolute serum creatinine increase ≥0.3 mg/dL; AKI-0.5, absolute serum creatinine increase ≥0.5 mg/dL; AKI-25, relative serum creatinine
increase ≥25%; NRI, net reclassification improvement.
*The following clinical variables, found at multivariate stepwise analysis, were considered: age, sex, left ventricular ejection fraction, admission serum creatinine, creatine kinase-MB peak.
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variables further improved mortality prognostication. More-
over, when the 3 AUCs were compared, AKI-0.5 was
associated with the highest improvement in mortality predic-
tion accuracy. At reclassification analysis, AKI-0.5 provided
the highest score in mortality risk, confirming its prognostic
superiority over the other 2 AKI definitions. In our study, the
net reclassification improvement of AKI-0.5 added to clinical
predictors of mortality was >8% and >28% for primary and
secondary end points, respectively, compared with both AKI-
0.25 and AKI-0.3.
Our findings agree with previous studies that investigated
the prognostic impact of absolute (≥0.5 mg/dL) and relative
(≥25% mg/dL) sCr increases among patients undergoing
elective or emergency PCI.24–26 Notably, all of these studies
showed that an absolute increase of ≥0.5 mg/dL was a better
predictor of short- and long-term outcomes than a ≥25%
increase. This result further supports the notion that AKI-0.5
should be the preferred definition for mortality prediction in
this setting, despite its lower expected sensitivity.
The reason why our study and previous ones suggested
that AKI-0.5 is a better indicator of mortality risk cannot be
inferred from our findings; however, we can suggest the
following hypotheses. Considering the nonlinear relationship
between sCr and GFR, an identical relative sCr increase is
associated with the same GFR percentage reduction inde-
pendent of the baseline sCr value.16 Conversely, an identical
absolute sCr increase is associated with a progressively lower
percentage reduction of GFR as baseline sCr value increases.
Consequently, an absolute cutoff takes into account both the
baseline number of functioning nephrons at hospital admis-
sion and the loss of nephrons due to AKI, and it appears to be
associated more strongly with mortality compared with a
variable reflecting the acute GFR decline only (Figure 3).
Indeed, the use of the AKI-0.5 definition is associated with a
significant GFR reduction in healthy kidneys and with a small
GFR decrease in vulnerable and already compromised
kidneys. In both cases, the diagnosis of AKI using the AKI-
0.5 definition translates into a striking mortality increase,
suggesting a relatively constant association of AKI-0.5 on
mortality regardless of baseline sCr. Overall, the AKI-0.5
definition for mortality prediction seems generalizable to
STEMI patients with varying degrees of baseline renal function
because it provides the highest score even when adjusted for
admission sCr.
Figure 3. Schematic representation of the nonlinear relationship between sCr and GFR (blue line)
measured at admission. When the AKI-0.5 definition was used, a progressively smaller GFR reduction (red
line) was observed in parallel with the increase in sCr measured at hospital admission. The mortality rates
observed in our study are reported according to admission sCr (allocated in 4 groups) and to AKI
occurrence. GFR drop was calculated by considering the mean age of our population (63 years). AKI
indicates acute kidney injury; AKI-0.5, absolute serum creatinine increase ≥0.5 mg/dL; GFR, glomerular
filtration rate; sCr, serum creatinine.
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Some clinical implications can be inferred from our study.
First, because of the important prognostic relevance of AKI,
its occurrence should always be looked for and diagnosed
after pPCI, independent of the definition used. Second, the
use of the AKI-0.5 definition allows better prediction of
mortality risk in this setting and, after the first 48 to 72 hours,
identification of very high-risk patients in whom additional
therapeutic strategies should be applied. Finally, the potential
impact of novel preventive and therapeutic approaches should
be evaluated and compared among studies, also taking into
account the incidence of AKI by using a standardized AKI-0.5
definition among the well-established hard end points.
Nevertheless, our findings warrant prospective validation in
larger studies.
A number of potential limitations to this study must be
addressed. First, exclusion of patients who died before having
2 consecutive sCr determinations reduced the overall mor-
tality rate in our population. Second, sCr measured at hospital
admission cannot be considered a true baseline value in
STEMI patients because an increase may have already
occurred before hospital admission. Third, we considered
only the AKI definitions that are used most frequently, thus we
cannot exclude the possibility that different absolute and/or
relative thresholds of sCr value may better assess mortality in
these patients. Fourth, we evaluated in-hospital outcomes
only; however, previous studies assessing the long-term
outcomes of STEMI patients found that the greatest mortality
difference between those with and without AKI1–3 was
observed during hospitalization. This was shown to be true
even when the criterion of 0.5 mg/dL sCr increase was
considered.27 Although increasing evidence suggests a detri-
mental role for AKI in chronic kidney disease development
and progression,16 we focused on the early STEMI phase.
Conclusions
Regardless of definition, AKI development has an incremental
predictive value beyond well-known clinical variables associ-
ated with in-hospital mortality in STEMI patients undergoing
pPCI. A mortality prognostication advantage is provided by the
AKI-0.5 definition, suggesting that this definition should be
preferred in clinical and interventional studies addressing
STEMI patients and focusing on short-term mortality.
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